Last edition
News about "Sun Pharma "
Sun Pharma Presents Long-Term Leqselvi Data
Sun Pharma presents long-term safety and efficacy data for Leqselvi in adults with severe alopecia areata at the EADV Congress 2026.
Sun Pharma | 03/10/2026 | By News Bureau
Sun Pharma joins White House ceremony highlighting US medicines pricing and access commitments, strengthening its presence across dermatology, immunology and generics.
Sun Pharma | 01/09/2026 | By News Bureau
Sun Pharma Reports Q1FY27 Results
Sun Pharma reported a 10.1 percent YoY rise in Q1 FY27 sales to INR 151,836 million, while net profit increased to INR 28,948 million, driven by strong business growth.
Sun Pharma | 01/08/2026 | By News Bureau | 240
Sun Pharma Acknowledges Organon Shareholder Approval for Acquisition
Sun Pharma has acknowledged Organon shareholders' approval of the proposed acquisition, marking a key milestone toward completion of the transaction.
Sun Pharma | 24/07/2026 | By News Bureau | 208
Sun Pharma Receives Approval to Manufacture and Market Generic Semaglutide in South Africa
Sun Pharma has received approval to manufacture and market generic semaglutide in South Africa, available as a once-weekly pre-filled multi-dose injectable pen in 2 strengths.
Sun Pharma | 15/07/2026 | By News Bureau | 100
Sun Pharma to Acquire Innovcare Lifesciences in INR 271 Crore Strategic Deal
Sun Pharma will acquire Innovcare Lifesciences for INR 271.2 crore, strengthening its presence in pharmaceuticals, nutraceuticals, and cosmeceuticals through the acquisition of the Mumbai-based healthcare company.
Sun Pharma | 22/06/2026 | By News Bureau | 128
Alembic Pharma Names Ramesh Juneja as EVP, Human Health
Alembic Pharmaceuticals has appointed Ramesh Juneja as Executive Vice President–Human Health for its India business. Bringing leadership experience from Sun Pharma, Cipla and Reliance Retail, Juneja will spearhead sales and marketing initiatives to drive growth in Alembic’s domestic pharmaceutical business.
Sun Pharma | 02/06/2026 | By News Bureau | 183
Sun Pharma Launches Semaglutide Injection in India Under Noveltreat and Sematrinity
Sun Pharmaceutical Industries has introduced semaglutide injections in India under the brands Noveltreat and Sematrinity, expanding access to advanced therapies for chronic weight management and type 2 diabetes. The launch strengthens treatment options with multiple dose strengths tailored to patient needs alongside diet and lifestyle interventions.
Sun Pharma | 21/03/2026 | By News Bureau | 819
The US FDA has accepted Sun Pharma’s supplemental BLA for ILUMYA to treat active psoriatic arthritis in adults, with a decision expected by 29 October, 2026, potentially expanding its IL-23 inhibitor portfolio.
Sun Pharma | 17/03/2026 | By News Bureau | 233
MHRA Clears Deuruxolitinib (Leqselvi) by Sun Pharma for Severe Alopecia Areata in Adults
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved deuruxolitinib (Leqselvi) for treating severe Alopecia Areata in adults, granting authorisation to Sun Pharma UK via the International Recognition Procedure (IRP).
Sun Pharma | 13/03/2026 | By News Bureau | 166
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy